Tue, Jul 22, 2014, 10:33 AM EDT - U.S. Markets close in 5 hrs 27 mins

Recent

% | $
Click the to save as a favorite.

Array BioPharma, Inc. Message Board

flannelhead69 5 posts  |  Last Activity: Jul 1, 2014 6:31 PM Member since: Mar 16, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Big pre-market trade

    by cl124cl Jul 1, 2014 9:13 AM
    flannelhead69 flannelhead69 Jul 1, 2014 6:31 PM Flag

    Yeah, him. Treated the company as his personal piggy bank, screwed up the dosing for 907, wasted time trying Debio 0932 as an IV drug and read up on the sham businesses of the one board member.

  • Reply to

    Big pre-market trade

    by cl124cl Jul 1, 2014 9:13 AM
    flannelhead69 flannelhead69 Jul 1, 2014 4:39 PM Flag

    Curis's management is a joke and will remain a joke as long as Fat Dan is around.

  • Reply to

    array partnership

    by hirtuism Jun 8, 2014 8:52 PM
    flannelhead69 flannelhead69 Jun 22, 2014 12:34 AM Flag

    Don't sleep on VTX-2337, some interesting tweets from LSINW this weekend. I missed that Celgene partnered with VentiRX to help bring VTX-2337 to market, but I like the legitimacy and know-how that Celgene brings. Been hoping that VTX-2337 would be paired with a checkpoint inhibitor modulator because everything I'd read made it sound like they'd work great together and was happy to see that it's going to happen.

    ARRY owns preferred equity in VentiRX and can get $56 million in milestone payments from this agreement, so it won't potentially be a huge source of revenue, but with all that ARRY has going on, it can be a part of a bunch of potential revenue sources that can add up.

    Sentiment: Strong Buy

  • Reply to

    array partnership

    by hirtuism Jun 8, 2014 8:52 PM
    flannelhead69 flannelhead69 Jun 9, 2014 3:45 PM Flag

    It's on the latest 10-Q: ARRY owns 19.9%, 3rd party valuation firm says the shares are worth $4.5 million. ARRY also owns preferred shares of VentiRX worth $1.5 million. Two of many reasons ARRY is a no-brainer investment.

    Sentiment: Strong Buy

  • flannelhead69 flannelhead69 May 27, 2014 9:18 PM Flag

    More like 40 Phase 2s. Ron has said there are 32 Phase 2s and above for Selumetinib, which makes 29 Phase 2s there and he's said there are 17 active Phase 1s and Phase 2s for Binimetinib. I count 16 at clinicaltrials and of those, 11 are Phase 2s.

    Sentiment: Strong Buy

ARRY
4.03+0.14(+3.60%)10:33 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.